Last kr2.72 SEK
Change Today -0.03 / -1.09%
Volume 262.6K
KAN On Other Exchanges
Symbol
Exchange
Stockholm
As of 12:00 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

kancera ab (KAN) Snapshot

Open
kr2.67
Previous Close
kr2.75
Day High
kr2.72
Day Low
kr2.66
52 Week High
01/20/14 - kr10.05
52 Week Low
10/15/13 - kr0.51
Market Cap
268.0M
Average Volume 10 Days
488.6K
EPS TTM
kr-0.22
Shares Outstanding
98.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KANCERA AB (KAN)

Related News

No related news articles were found.

kancera ab (KAN) Related Businessweek News

No Related Businessweek News Found

kancera ab (KAN) Details

Kancera AB, a biotechnology company, engages in the development and sale of drug candidates that cure or stop the progression of cancer. Its pharmaceutical development projects include PFKFB3 project, which targets the ability of solid tumors, such as breast, prostate, lung, and colon cancer to survive and resist chemotherapy and radiotherapy treatment; and ROR-1 project that aims to develop a targeted drug to treat chronic lymphatic leukemia. The company was founded in 2010 and is based in Solna, Sweden.

Founded in 2010

kancera ab (KAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kancera ab (KAN) Key Developments

Kancera AB Announces Earnings Results for the First Quarter Ended March 31, 2014

Kancera AB announced earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net sales of SEK 212,000. Operating loss was SEK 4,149,000 against SEK 2,311,000 a year ago. Financial loss was SEK 24,000 against financial income of SEK 3,001,000 a year ago. Loss after financial items was SEK 4,173,000 against income after financial items of SEK 690,000 a year ago. Net loss was SEK 4,173,000 against net income of SEK 690,000 a year ago. Loss per share, before and after dilution was SEK 0.06 against EPS of SEK 0.04 a year ago. Cash flow used in operating activities was SEK 3,173,000 against SEK 2,236,000 a year ago. Investment in tangible assets was SEK 500,000 against SEK 2,000 a year ago. Negative free cash flow available to investors was SEK 3,673,000 against SEK 4,236,000 a year ago. For the period, the company reported negative return on equity and negative return on capital employed. Cash flow per share was SEK 0.08 against SEK 0.01 a year ago. Kancera´s activities have mainly covered internal drug development projects alongside smaller consultancy projects which raised net sales during the period of SEK 0.2 million.

Kancera AB Reports Earnings Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Kancera AB reported earnings unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net turnover of SEK 1,354,000. Operating loss was SEK 2,083,000 against SEK 1,705,000 a year ago. Net loss was SEK 2,096,000 or SEK 0.05 per share, before and after dilution against SEK 4,025,000 or SEK 0.22 per share, before and after dilution a year ago. Cash flow from operating activities was SEK 363,000 against cash used in operating activities of SEK 7,187,000 a year ago. Return on equity was negative. Cash-flow by share was SEK 0.31 against SEK 0.13 a year ago. For the year, the company reported net turnover of SEK 1,813,000. Operating loss was SEK 10,404,000 against SEK 21,245,000 a year ago. Net loss was SEK 7,418,000 or SEK 0.22 per share, before and after dilution against SEK 23,502,000 or SEK 1.42 per share, before and after dilution a year ago. Cash flow used in operating activities was SEK 6,641,000 against SEK 22,535,000 million a year ago. Return on equity was negative. Cash-flow by share was SEK 0.27 against SEK 0.57 a year ago.

Kancera AB to Report Fiscal Year 2013 Final Results on May 05, 2014

Kancera AB announced that they will report fiscal year 2013 final results on May 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KAN:SS kr2.72 SEK -0.03

KAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KAN.
View Industry Companies
 

Industry Analysis

KAN

Industry Average

Valuation KAN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 89.4x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 115.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KANCERA AB, please visit www.kancera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.